Company

PYC Therapeutics Limited

Headquarters: Nedlands, WA, Australia

CEO: Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)

ASX: PYC +927.03%

Market Cap

A$657.1 Million

AUD as of July 1, 2024

US$437.6 Million

Market Cap History

PYC Therapeutics Limited market capitalization over time

Evolution of PYC Therapeutics Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of PYC Therapeutics Limited

Detailed Description

PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

PYC Therapeutics Limited has the following listings and related stock indices.


Stock: ASX: PYC wb_incandescent

Details

Headquarters:

Harry Perkins Institute of Medical Resea

6 Verdun Street

Nedlands, WA 6009

Australia

Phone: 61 8 6151 0994